← All stocks

Stock news timeline · METROPOLIS

Metropolis Health.

News timeline · Last 30 days

23 Aug 2026 – 21 Sep 2026 · Times in IST

Timeline updates
11
Bullish
3
Neutral
8
Bearish
0
Active days
5

News timeline

Showing 11 of 11 updates · Newest first

Wednesday, 09 Sep 20261 update

AI sentiment: Neutral 90% confidence

Metropolis Issues 66,312 Shares at ₹2 Each Under RSU Plan

Metropolis Healthcare approved allotment of 66,312 equity shares under MHL-RSU Plan, 2020 at INR 2/share. Shares will rank pari-passu with existing equity; 50% under 1-year lock-in till September 2027. Source: BSE

Monday, 07 Sep 20263 updates

AI sentiment: Neutral 83% confidence

Metropolis Healthcare: Subsidiary MQSPL Partners With MedSource, Holding 54.90% Stake After Conversion.

AI sentiment: Neutral 88% confidence

Metropolis Restructures MQSPL Stake: MHL Retains 54.9%

Metropolis Healthcare's subsidiary MQSPL restructures via agreements with Medsource and Dr. Puneet Nigam. Post-restructuring, MQSPL's shareholding will be MHL 54.9%, Medsource 30.6%, Dr. Puneet 14.5%. Source: BSE

AI sentiment: Neutral 93% confidence

Franklin Templeton Buys 0.36% Stake in Metropolis Healthcare

Franklin Templeton Mutual Fund acquired 742,409 shares of Metropolis Healthcare Ltd. The shares, constituting 0.36% of share capital, were bought via open market. Source: ScoutQuest

Thursday, 03 Sep 20261 update

AI sentiment: Neutral 73% confidence

Metropolis Healthcare: Aims for 2,500 Crore Annual Organic Revenue in Three-Year Plan - ET

Friday, 28 Aug 20264 updates

AI sentiment: Neutral 64% confidence

ICICI Sec: 'Buy' Metropolis, Sets ₹675 Target on 29% Earnings Growth

ICICI Securities maintains 'Buy' on Metropolis Healthcare, citing 29% earnings CAGR FY26–28E, 15% revenue CAGR. Target price set at Rs 675; risks include competition, regulation, but growth driven by M&A, geographic expansion. Source: NDTV Profit

AI sentiment: Bullish 79% confidence

Metropolis Eyes 14-15% Revenue Growth by FY29

Metropolis projects a 14-15% revenue growth for FY27-29 in its roadmap. Source: ScoutQuest

AI sentiment: Bullish 82% confidence

Kotak Sets ₹655 Target for Metropolis, Sees Strong Growth Ahead

Kotak Institutional Equities rates Metropolis Healthcare 'Add' with a ₹655 target price. Steady 14–15% FY27E sales growth and +300 bps EBITDA margin rise expected by FY29. Source: Livesquawk

AI sentiment: Bullish 89% confidence

Kotak Institutional Equities Keeps "Add" Rating On Metropolis Healthcare With Target Price Set At ₹655, As 14-15% FY27E Sales Growth Is Expected To Remain Steady, Fueled By Increasing TruHealth/Specialty Services Mix And Network Maturity, Anticipating A 300 Basis Points EBITDA Margin Growth From FY26 To FY29.

Thursday, 27 Aug 20262 updates

AI sentiment: Neutral 78% confidence

Metropolis Moves EQAS Biz to Subsidiary for ₹1.25 Cr

Metropolis Healthcare shifted EQAS business to subsidiary MQSPL via slump sale for INR 1.25 crore. Transaction involves equity shares issued to parent, effective August 27, 2026. Source: ScoutQuest

AI sentiment: Neutral 85% confidence

Metropolis Plans 1,000 Centers, Targets 45% Specialty Revenue

Metropolis Healthcare shared its Investor Presentation under SEBI Regulation 30, outlining its strategic growth plans, including expanding its network to 1,000 centers and increasing specialty revenue to 45%. FY26 revenue grew at 17.6% CAGR to ₹1,646 Cr; plans include AI-driven automation, genomics expansion, and selective M&A to enhance profitability and shareholder value. Source: BSE